Cyclin D1 in invasive breast carcinoma: Favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype

Histopathology

Volumn 62, Issue 3, 2013, Pages 472-480

  Mylona, Eleni ^a   Tzelepis, Konstantinos ^b   Theohari, Irene ^b   Giannopoulou, Ioanna ^b   Papadimitriou, Christos ^b   Nakopoulou, Lydia ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Cyclin D1; Immunohistochemistry; Prognosis

Indexed keywords

CYCLIN D1; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLIN D1; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84872670110     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12013     Document Type: Article

References (40)

1. Roberti A, Macaluso M, Giordano A. Alterations in cell cycle regulatory genes in breast cancer. Curr. Clin. Oncol. 2009; 3; 56-77.
2. Morgan DO. Principles of CDK regulation. Nature 1995; 374; 131-134.
3. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 2009; 220; 292-296.
4. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 2005; 23; 4215-4224.
5. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145; 5439-5447.
6. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl Acad. Sci. USA 1994; 91; 8022-8026.
7. Han EK, Sgambato A, Jiang W et al. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 1995; 10; 953-961.
8. Han EK, Begemann M, Sgambato A et al. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth and enhances apoptosis. Cell Growth Differ. 1996; 7; 699-710.
9. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002; 4; 14-17.
10. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer 1996; 69; 92-99.
11. van Diest PJ, Michalides RJA, Jannink I et al. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am. J. Pathol. 1997; 150; 705-711.
12. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol. Rep. 2002; 9; 409-416.
13. Huang TS, Han HS, Hong YC, Lee HJ, Paik N-S. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol. Int. 2003; 53; 74-80.
14. Bilalović N, Vranić S, Basić H, Tatarević A, Selak I. Immunohistochemical evaluation of cyclin D1 in breast cancer. Croat. Med. J. 2005; 46; 382-388.
15. Reis-Filho JS, Savage K, Lambros MBK et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic insitu hybridization analysis. Mod. Pathol. 2006; 19; 999-1009.
16. Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn. J. Clin. Oncol. 2007; 37; 708-714.
17. Hadžisejdić I, Mustać E, Jonjić N, Petković M, Grahovac B. Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis. Mod. Pathol. 2010; 23; 392-403.
18. Michalides R, Hageman P, van Tinteren H et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer 1999; 73; 728-734.
19. Umekika Y, Ohi Y, Sagara Y, Yoshida H. Overexression of cyclin D1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int. J. Cancer 2002; 98; 415-418.
20. Roy PG, Pratt N, Purdie CA et al. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int. J. Cancer 2010; 127; 355-360.
21. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
22. Cummings MC, Chambers R, Simpson P, Lakhani SR. Molecular classification of breast cancer: is it time to pack up our microscopes?Pathology 2011; 43; 1-8.
23. Robins P, Pinder S, de Klerk N. Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol. 1995; 6; 873-879.
24. Union International Contre Cancer. TNM Classification of International Union against Cancer. In Hermanenek R, Sabin H eds. TNM atlas, 3rd revision, 4th edn. Berlin: Springer-Verlang, 1992; 15-25.
25. Nakopoulou L, Lazaris AC, Kavantzas N et al. DNA topoisomerase IIalpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000; 68; 137-143.
26. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris CA, Tzonou A, Keramopoulos A. Prognostic significance of the co-expression of p53 and c-erbB2 proteins in breast cancer. J. Pathol. 1996; 179; 31-38.
27. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 2786-2795.
28. Wolff AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
29. Sotiriou C, Neo S-Y, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 2003; 100; 10393-10398.
30. Pelosio P, Barbareschi M, Bonoldi E et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann. Oncol. 1996; 7; 695-703.
31. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol. 1994; 102; 695-698.
32. Peters G, Fantl V, Smith R, Brookes S, Dickson C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res. Treat. 1995; 33; 125-135.
33. Quelle DE, Ashmun RA, Shurtleff SA et al. Overxpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993; 7; 1559-1571.
34. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. Acetylation control of the retinoblastoma tumor-suppressor. Nat. Cell Biol. 2001; 3; 667-674.
35. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc. Natl Acad. Sci. USA 1999; 96; 5382-5387.
36. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl Acad. Sci. USA 1999; 96; 11217-11222.
37. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88; 405-415.
38. Neuman E, Ladha MH, Lin N et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 1997; 17; 5338-5347.
39. Kenny FS, Hui R, Musgrove EA et al. Overexression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 1999; 5; 2069-2076.
40. Gauthier ML, Berman HK, Miller C et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007; 12; 479-491.